Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Pyxis Oncology Inc (NASDAQ: PYXS) was $4.83 for the day, up 2.99% from the previous closing price of $4.69. In other words, the price has increased by $2.99 from its previous closing price. On the day, 0.57 million shares were traded. PYXS stock price reached its highest trading level at $5.08 during the session, while it also had its lowest trading level at $4.74.
Ratios:
Our analysis of PYXS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.84 and its Current Ratio is at 4.84. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on February 09, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On January 23, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $12.
On September 05, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $7.RBC Capital Mkts initiated its Outperform rating on September 05, 2023, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 28 ’23 when Connealy Pamela Ann bought 8,000 shares for $1.87 per share. The transaction valued at 14,960 led to the insider holds 818,532 shares of the business.
Connealy Pamela Ann bought 6,426 shares of PYXS for $11,868 on Sep 27 ’23. The CFO and COO now owns 810,532 shares after completing the transaction at $1.85 per share. On Sep 27 ’23, another insider, Wadhane Jitendra, who serves as the Chief Accounting Officer of the company, bought 2,500 shares for $1.87 each. As a result, the insider paid 4,675 and bolstered with 226,937 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 280784320 and an Enterprise Value of 174678528.
Stock Price History:
The Beta on a monthly basis for PYXS is 1.43, which has changed by 0.45921445 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $6.85, while it has fallen to a 52-week low of $1.35. The 50-Day Moving Average of the stock is -5.12%, while the 200-Day Moving Average is calculated to be 68.03%.
Shares Statistics:
PYXS traded an average of 909.90K shares per day over the past three months and 526860 shares per day over the past ten days. A total of 58.13M shares are outstanding, with a floating share count of 46.27M. Insiders hold about 20.40% of the company’s shares, while institutions hold 29.04% stake in the company. Shares short for PYXS as of 1711584000 were 2702190 with a Short Ratio of 2.97, compared to 1709164800 on 1338986. Therefore, it implies a Short% of Shares Outstanding of 2702190 and a Short% of Float of 5.58.
Earnings Estimates
The current market rating for Pyxis Oncology Inc (PYXS) reflects the collective analysis of 5 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.34, while EPS last year was -$0.55. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.12 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.27 and -$1.19 for the fiscal current year, implying an average EPS of -$0.91. EPS for the following year is -$1.2, with 5 analysts recommending between -$0.94 and -$1.45.
Revenue Estimates
Based on 4 analysts’ estimates, the company’s revenue will be $500k in the next fiscal year. The high estimate is $2M and the low estimate is –$. The average revenue growth estimate for next year is down -88.90% from the average revenue estimate for this year.
